Praxis Precision Medicines, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing was signed March 5, 2024. Praxis is a clinical-stage biopharmaceutical company developing CNS therapies; it has no approved products and has not generated product-sales revenue.
Business context and pipeline
Praxis develops therapies through its Cerebrum small-molecule platform and Solidus antisense oligonucleotide (ASO) platform. Its four clinical-stage candidates target essential tremor and epilepsy-related conditions:
- Ulixacaltamide: Phase 3 Essential3 program for essential tremor; enrollment was expected to complete in the first half of 2024, with topline results expected in the second half of 2024 and a potential NDA filing in 2025.
- PRAX-628: In a Phase 2a photo-paroxysmal response study; topline results were expected in the first quarter of 2024. A Phase 2b focal epilepsy study was planned for the second half of 2024.
- PRAX-562: Phase 2 EMBOLD study in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs); topline results were expected in mid-2024.
- Elsunersen (PRAX-222): The initial open-label portion of the EMBRAVE study in SCN2A-DEE completed in the fourth quarter of 2023. Praxis reported no treatment-related adverse events or serious adverse events in that portion and described observed seizure reductions; a pivotal phase was anticipated later in 2024, subject to regulatory interactions.
Financial results and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Collaboration revenue | $2.4 million | None reported |
| Research and development expense | $86.8 million | $155.0 million |
| General and administrative expense | $42.1 million | $59.9 million |
| Total operating expenses | $128.8 million | $215.0 million |
| Operating loss | $126.4 million | $215.0 million |
| Other income, net | $3.1 million | $1.0 million |
| Net loss | $123.3 million | $214.0 million |
| Net loss per share, basic and diluted | $18.69 | $69.65 |
| Net cash used in operating activities | $111.1 million | $185.0 million |
Revenue was collaboration revenue from UCB research services, not product sales. Gross margin and product margins are not meaningful for this pre-commercial company; the filing does not report a product-sales margin. R&D spending fell $68.3 million, primarily due to reduced Cerebrum program spending and lower personnel costs. G&A declined $17.9 million, mainly from lower professional fees and personnel costs. Net loss narrowed by $90.8 million.
At December 31, 2023, Praxis had $81.3 million of cash and cash equivalents, no marketable securities, $84.9 million of current assets and $15.7 million of current liabilities. Stockholders’ equity was $69.7 million; accumulated deficit was $653.9 million. No debt balance is reported in the supplied financial statements. The company reported no income tax provision for either year. Operating cash outflow improved from $185.0 million to $111.1 million; financing provided $91.9 million in FY2023, largely from a June public offering and at-the-market sales.
Material changes, outlook and notable items
- Praxis said cash on hand plus January 2024 financing and ATM proceeds was expected to fund operations and planned clinical work into 2026. Separately, the financial-statement liquidity assessment said those resources were expected to fund operations for at least one year from issuance. Both are management estimates and depend on assumptions; the company expects continuing losses and says additional capital will be needed.
- In January 2024, Praxis raised approximately $161.7 million net from a public offering and $5.3 million net through its ATM program. It also entered a Tenacia agreement for ulixacaltamide in Greater China, receiving $5.0 million upfront and approximately $10.0 million from a related stock sale; it may receive up to $264.0 million in milestones plus royalties.
- Under the UCB agreement, Praxis recognized $2.4 million of revenue in 2023 and had $2.6 million of deferred revenue at year-end. UCB may exercise an option to develop and commercialize resulting KCNT1 candidates; potential milestones total up to $98.5 million plus royalties.
- Praxis paid Ionis $6.9 million in July 2023 for a milestone and related interest after starting the EMBRAVE study. Future milestone, royalty and sublicense obligations may apply under its license arrangements.
- A 1-for-15 reverse stock split took effect November 28, 2023; share and per-share figures in the filing are retroactively adjusted. The June 2023 offering included 470,000 outstanding pre-funded warrants exercisable for nominal consideration.
- A 2022 strategic realignment and workforce reduction resulted in $1.0 million of costs, all paid by year-end 2022. The company also disclosed that an earlier ulixacaltamide Aria study did not meet its primary endpoint, contributing to historical stock-price volatility.
- The principal risks include clinical-trial efficacy, safety, enrollment and timing; regulatory approval; competition; dependence on external manufacturers, CROs and collaborators; intellectual-property protection and licensing; and the need for further financing. Praxis has no manufacturing facilities and relies on third parties.
Investor verification priorities
- Check the final results and statistical details for Essential3, PRAX-628’s PPR study, PRAX-562’s EMBOLD cohorts and the next-stage plans for elsunersen against subsequent filings and trial disclosures.
- Reconcile the stated runway into 2026 with the more limited “at least one year from issuance” liquidity assessment, and monitor actual cash burn and financing needs.
- Verify the terms, receipt and use of January 2024 financing and Tenacia consideration, including dilution from common shares and pre-funded warrants.
- Review collaboration economics and contingent obligations, including Ionis and RogCon payments and UCB and Tenacia milestones and royalties.
- Assess whether trial data, including preliminary or open-label findings, are confirmed in controlled studies and support regulatory requirements; monitor adverse events and enrollment progress.
- Review the audited financial statements and disclosures on R&D accrual estimates. The auditor issued an unqualified opinion on the financial statements and identified Cerebrum accrued and prepaid R&D costs as a critical audit matter.